Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Ontology highlight
ABSTRACT: The management of advanced-stage renal cell carcinoma (RCC) has been transformed by the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not derive durable clinical benefit from these agents. Importantly, unlike other immunotherapy-responsive solid tumours, most RCCs have only a moderate mutational burden, and paradoxically, high levels of tumour CD8+ T cell infiltration are associated with a worse prognosis in patients with this disease. Building on the successes of antibodies targeting the PD-1 and CTLA4 immune checkpoints, multiple innovative immunotherapies are now in clinical development for the treatment of patients with RCC, including ICIs with novel targets, co-stimulatory pathway agonists, modified cytokines, metabolic pathway modulators
SUBMITTER: Braun DA
PROVIDER: S-EPMC8317018 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA